Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Anaplastic thyroid cancer, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Most people diagnosed still die within a year, and the MD Anderson series that lifted one-year survival from about a fifth to over half came from one centre combining BRAF-targeted drugs, immunotherapy, surgery and radiotherapy; whether that holds outside specialist centres is what prospective work has to establish.
BRAF wild-type disease has no targeted option.
Trials are tiny because the disease is rare and fast.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer
Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
A milestone in how this cancer is treated.
The first drug approval for this cancer.
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma